Home > Boards > Stock Clubs > Market Trends and Strategies > $heff's $tation of $tocks & $olid DD

sheff, as far as ANX now is the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
06mets Member Profile
 
Followed By 31
Posts 4,337
Boards Moderated 0
Alias Born 12/19/06
160x600 placeholder
Mastercard on Track for Lowest Close in Over a Year -- Data Talk
Mastercard Incorporated Class A (MA) is currently at $313.17, down $9.84 or 3.05%
Shell's Deer Park Texas Refinery Sale Delayed, Reuters Reports
Activision on Track for Longest Losing Streak Since January 2014 -- Data Talk
Cumberland Pharmaceuticals Shares Double, Hit 52-Week High
STOXX Europe 600 Index Ends the Month 2.64% Lower at 462.96 -- Data Talk
FTSE 100 Index Ends the Month 2.46% Lower at 7059.45 -- Data Talk
DAX Ends the Month 3.75% Lower at 15100.13 -- Data Talk
CAC 40 Index Ends the Month 1.60% Lower at 6721.16 -- Data Talk
STOXX Europe 50 Index Ends the Month 2.57% Lower at 3593.42 -- Data Talk
EURO STOXX 50 Index Ends the Month 4.41% Lower at 4063.06 -- Data Talk
U.S. Crude-Oil Stockpiles Likely Decreased in DOE Data, Analysts Say
FTSE Closes Down as Omicron Variant Sparks Volatility
Cabot Properties Sells Logistics Portfolio to Blackstone for $2.8 Billion
Oersted Secures 12-Year Power Purchase Contract With Google
Array Technologies Shares Fall With Plans for Convertible Notes Offering
Top Company News of the Day
U.S. Ethanol Production and Stocks Estimates for Nov. 26
TG Therapeutics Shares Drop 38% After Plans for Advisory Meeting
Consumer Confidence Fell in November Amid Inflation Worries
Clarus Therapeutics Shares Rise 27% on New U.S. Patents
Unemployment Rate Seen Ticking Down Again -- Data Week Ahead
MEI Pharma Shares Rise 22% After Positive Data for Zandelisib Trial
TG Therapeutics Shares Drop 35% Premarket After FDA Plans for Advisory Meeting
Codiak BioSciences Gets FDA Approval for ExoASO-STAT6 IND Application
MTN Group to Cut Stake in MTN Nigeria Via Share Placing
AbbVie Submits Europe Application for Risankizumab for Crohn's Disease
Hepion Pharmaceuticals Gets Fast-Track Designation for NASH Treatment
NextEra to Sell 50% Stake in Renewables Portfolio to Ontario Teachers' Pension Plan
Right Time for New Leadership, Inditex Chairman Says, as Founder's Daughter Prepares to Take His Place -- Update
Stellantis, Daimler's Mercedes-Benz Invest in Battery Maker Factorial Energy
06mets   Tuesday, 12/18/07 02:05:55 AM
Re: $heff post# 751
Post # of 97235 
sheff, as far as ANX now is the time, ANX is trading at cash value, tax selling is all but over, vinerolbine results will be out soon(company is very optimistic on the results), insiders are loading up down here, and despite the cofactor phase 2b findings which didnt meet expectations(they are still pursuing cofactor for breast cancer), they are actively pursuing a partnership with a big pharma and they have a robust pipeline of drugs wwhich they r very high on, plus carl icahn is one of the largest shareholders, .47 is ridiculous for this stock, i see it going to a buck quick, keep in mind it was 5.40 not to long ago, if your looking for a nice quick gainer ANX is the play imo

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences